Hospital
Pemiscot County Memorial Hospital
Pemiscot County Memorial Hospital was paid $10.17M by Medicaid between Jan 2018 and Nov 2024, across 125 billing codes. Its largest line is 99285, emergency room visit (most serious) — 9.2% of everything it billed.
33Billing provider infoPEMISCOT COUNTY MEMORIAL HOSPITAL
HAYTI, MO 63851
HAYTI, MO 63851
33aNPI1437179710assigned 07/20/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$10.17M
24GClaims229,782
24DCodes billed125
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Missouri
Rank by total paid#4 of 9
Median peer was paid$8.82M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,604 | $2.49M | |
| 2019 | 48,155 | $2.32M | |
| 2020 | 17,519 | $829K | |
| 2021 | 27,474 | $973K | |
| 2022 | 40,176 | $1.62M | |
| 2023 | 30,350 | $1.19M | |
| 2024incomplete | 16,504 | $748K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.2% | 4,435 | 3,855 | $935K |
| Y7506 | 8.1% | 14,519 | 11,912 | $819K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.5% | 4,434 | 4,016 | $663K |
| X4011 | State-specific procedure code | 6.4% | 4,665 | 3,691 | $647K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.3% | 5,815 | 5,286 | $643K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.6% | 12,990 | 11,763 | $567K |
| 80053 | Comprehensive metabolic panel | 4.4% | 20,667 | 15,681 | $451K |
| X4006 | 4.3% | 2,087 | 1,709 | $437K | |
| 62323 | 4.2% | 3,688 | 3,130 | $430K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.0% | 20,881 | 15,886 | $411K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.8% | 3,035 | 2,839 | $386K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.8% | 4,040 | 3,742 | $280K |
113 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.7% | 8,555 | $273K |
| J3490 | Unclassified drugs | 2.5% | 13,440 | $251K |
| 71045 | Radiologic examination, chest; single view | 2.2% | 6,736 | $228K |
| G0378 | Hospital observation service, per hour | 1.8% | 1,602 | $183K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.4% | 4,145 | $141K |
| 82550 | 1.4% | 6,895 | $139K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.3% | 742 | $135K |
| 72100 | 1.2% | 4,836 | $125K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.2% | 1,525 | $124K |
| 62321 | 1.2% | 950 | $120K | |
| 84484 | 1.1% | 6,300 | $110K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 1,351 | $103K |
| 81001 | 1.0% | 5,618 | $102K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,279 | $82K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 970 | $80K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,339 | $74K |
| 82553 | <1% | 4,572 | $73K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,845 | $73K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,072 | $66K |
| 83690 | <1% | 1,172 | $66K | |
| 82150 | <1% | 1,062 | $65K | |
| 83880 | <1% | 2,590 | $60K | |
| 85610 | <1% | 3,226 | $59K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 546 | $58K |
| 64483 | <1% | 234 | $56K | |
| 85730 | <1% | 3,075 | $52K | |
| 20610 | <1% | 890 | $48K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,579 | $44K |
| 80061 | Lipid panel | <1% | 2,016 | $36K |
| 72141 | <1% | 327 | $32K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 697 | $31K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,816 | $28K |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 792 | $26K |
| 72040 | <1% | 1,178 | $25K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 899 | $24K |
| 64493 | <1% | 79 | $23K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 398 | $20K |
| 83735 | <1% | 598 | $17K | |
| 52224 | <1% | 46 | $17K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 720 | $16K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 690 | $16K |
| 80305 | <1% | 677 | $16K | |
| 94760 | <1% | 448 | $15K | |
| 20552 | <1% | 178 | $13K | |
| 83605 | <1% | 793 | $12K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 559 | $12K |
| 87040 | <1% | 939 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 706 | $10K |
| 81025 | <1% | 224 | $9K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 72 | $9K |
| 80050 | General health panel | <1% | 82 | $7K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,888 | $7K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 336 | $6K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 604 | $6K |
| 72202 | <1% | 302 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 14 | $5K |
| 87807 | <1% | 361 | $5K | |
| 52351 | <1% | 31 | $5K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 101 | $5K |
| 73560 | <1% | 261 | $5K | |
| 86618 | <1% | 27 | $3K | |
| 82803 | <1% | 274 | $3K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 21 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 27 | $3K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 37 | $2K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 25 | $2K |
| 81003 | <1% | 638 | $2K | |
| 86677 | <1% | 31 | $2K | |
| 36600 | <1% | 69 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 31 | $2K |
| 90837 | Psychotherapy session, about an hour | <1% | 102 | $1K |
| 93226 | <1% | 46 | $1K | |
| 73020 | <1% | 60 | $1K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $996.06 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 277 | $908.44 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 221 | $904.60 |
| 82607 | <1% | 72 | $859.72 | |
| 72131 | <1% | 26 | $836.56 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 69 | $635.24 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 164 | $490.92 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 82 | $452.64 |
| 85027 | <1% | 110 | $441.67 | |
| 84439 | <1% | 58 | $439.51 | |
| 27096 | <1% | 19 | $406.08 | |
| 84703 | <1% | 75 | $374.99 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16 | $374.35 |
| 82948 | <1% | 155 | $326.21 | |
| 84153 | <1% | 19 | $263.55 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $245.18 |
| 0011A | <1% | 18 | $230.40 | |
| 85651 | <1% | 109 | $219.75 | |
| 86592 | <1% | 16 | $168.29 | |
| 80076 | <1% | 12 | $80.70 | |
| 84480 | <1% | 13 | $70.43 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,219 | $38.48 |
| 84436 | <1% | 13 | $32.42 | |
| 99070 | <1% | 2,352 | $29.63 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,335 | $1.22 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 188 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 19 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 104 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 36 | $0.00 |
| 64495 | 0% | 39 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 14 | $0.00 |
| 93229 | 0% | 16 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 13 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 76 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 67 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 27 | $0.00 |
| 64494 | 0% | 39 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 15 | $0.00 |
| G1007 | Clinical decision support mechanism aim specialty health, as defined by the medicare appropriate use criteria program | 0% | 18 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTURNAGE, LAUREN (REVENUE CYCLE DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Pemiscot County Memorial Hospital | Hayti, MO | $6.56M |
| Pemiscot County Memorial Hospital | Kennett, MO | $1.29M |
| Pemiscot County Memorial Hospital | Hayti, MO | $1.14M |
| Pemiscot County Memorial Hospital | Hayti, MO | $1.06M |
| Pemiscot County Memorial Hospital | Caruthersville, MO | $634K |
| Pemiscot County Memorial Hospital | Steele, MO | $373K |
| Pemiscot County Memorial Hospital | Caruthersville, MO | $331K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.